Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease. [electronic resource]
Producer: 20170222Description: 247-54 p. digitalISSN:- 1332-8166
- Adult
- Aged
- Antineoplastic Agents -- administration & dosage
- Dasatinib -- administration & dosage
- Female
- Graft vs Host Disease
- Humans
- Imatinib Mesylate -- administration & dosage
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- therapy
- Male
- Middle Aged
- Retrospective Studies
- Salvage Therapy
- Sclerosis -- complications
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.